Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.
Wellens J., Edmans M., Obolski U., McGregor CG., Simmonds P., Turner M., Jarvis L., Skelly D., Dunachie S., Barnes E., Eyre DW., Colombel J-F., Wong S-Y., Klenerman P., Lindsay JO., Satsangi J., Thompson CP.